Market Assessment
Allergan (AGN) is a commercial-stage large market cap ($45.9B) biopharma developing innovative and generic therapeutics for diseases affecting the eyes, bowel, lungs, skin, urogenital systems and brain. Through the acquisition of Tobira Therapeutics, Allergan has been clinically developing cenicriviroc ((CVC)) as a potential therapy for the chronic liver disease, NASH. Allergan is also developing in-house investigative drug candidates for NASH that pharmacologically targets the farnesoid X receptor ((FXR)).
As a dual CCR2/CCR5 chemokine receptor antagonist with well documented immune modulatory effects, CVC is unique in its selective suppressive functional effects